
Roche

This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others:

1 pricing and product initiatives of competitors;
2 legislative and regulatory developments and economic conditions;
3 delay or inability in obtaining regulatory approvals or bringing products to market;
4 fluctuations in currency exchange rates and general financial market conditions;
5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products;
6 increased government pricing pressures;
7 interruptions in production;
8 loss of or inability to obtain adequate protection for intellectual property rights;
9 litigation;
10 loss of key executives or other employees; and
11 adverse publicity and news coverage.

Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche’s earnings or earnings per share for this year or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche.

For marketed products discussed in this presentation, please see full prescribing information on our website www.roche.com

Roche

YTD September 2022 sales

Basel, 18 October 2022

Group

Severin Schwan
Chief Executive Officer

YTD Sep 2022 performance

Outlook

YTD Sep 2022: Group sales +2% despite COVID-19 decline in Q3

Group sales +2% driven by Diagnostics division

- Pharma with stable performance, key products compensating for LOEs and declining COVID-19 sales
- Diagnostics with good growth momentum (+6%) including good base business growth (+6%)

Key products growing strongly; new launches with significant sales potential

- Pharma growth drivers Ocrevus, Hemlibra, Evrysdi, Phesgo, Vabysmo and Tecentriq with strong momentum
- Promising new launches with Vabysmo in ophthalmology and Polivy & Lunsumio in hematology
- New launches of next generation of SARS-CoV-2 rapid antigen test 2.0, Prame immunohistochemistry assay for melanoma and Digital LightCyler

Upcoming late-stage newsflow in 2022

- Pharma: Gantenerumab in Alzheimer's disease; Venclexta in MM (t11;14); Vabysmo in RVO; Susvimo in DME & DR
- Diagnostics: Elecsys® pTau/AB42 ratio Gen2 CSF (FDA), cobas® 5800 (FDA)

Growth rates at CER (Constant exchange Rates); LOE=loss-of-exclusivity

YTD Sep 2022: Group sales growth driven by Diagnostics Division

	2022 CHFbn	2021 CHFbn	Change in % CHF	Change in % CER
Pharmaceuticals Division	33.2	33.4	-1	0
Diagnostics Division	13.8	13.3	4	6
Roche Group	47.0	46.7	1	2

CER=Constant Exchange Rates; totals may include differences due to rounding

Quarterly sales performance: COVID-19 sales coming down



Growth rates at CER (Constant Exchange Rates); * Q2 2020 sales severely impacted by COVID-19 pandemic onset; [1]AHR: Avastin, Herceptin, Rituxan/MabThera

YTD Sep 2022: Portfolio rejuvenation ongoing



Diversification of Roche business



YTD Sep 2022 values in reported CHFm, variances in CERm; [1] AHR: Avastin, Herceptin, Rituxan/MabThera sales erosion

YTD Sep 2022: Solid underlying sales growth in both divisions

Pharma
Quarterly sales evolution 2021-2022



Diagnostics
Quarterly sales evolution 2021-2022



Growth rates at CER (Constant Exchange Rates); [1] Excl. Ronapreve and Actemra

YTD Sep 2022 performance

Outlook

Continuous increase in pipeline breadth and depth

All-time high for Ph III AIs and industry-leading number of NMEs in the clinic

Projects in Ph III & registration



Record number of NMEs and AIs (YTD Sep 2022)



NME=new molecular entity; AI=additional indication

2022/23: Upcoming Pharma newsflow

2022	2023
Vabysmo in RVO	**Tiragolumab + Tecentriq** in 1L PDL1+ NSCLC
Susvimo in DME	**Tiragolumab + Tecentriq** in 1L Esophageal
Susvimo in DR	**Tecentriq** in adjuvant HCC
Venclexta in R/R MM (t11;14)	**Tecentriq** in adjuvant SCCHN
Gantenerumab in Alzheimer's disease	**Tecentriq + chemo** in adjuvant TNBC
	Tecentriq neoadjuvant/adjuvant TNBC
	Tecentriq periadjuvant NSCLC
	Phesgo OBI in HER2+ BC
	Alecensa in adjuvant ALK+ NSCLC
	Venclexta in 1L high risk MDS
	Crovalimab in PNH
	Glofitamab in 2L+ DLBCL*
	Lunsumio in 2L+ DLBCL*
	Delandistrogene moxeparvovec in DMD
	Ocrevus SC in RMS / PPMS
	TNKase in Stroke
	Xolair in Food allergy

Neuroscience
Oncology
Ophthalmology
Immunology

DME=diabetic macular edema; DLBCL=diffuse large B-cell lymphoma; NSCLC=non-small cell lung cancer; HCC=hepatocellular carcinoma; MM=multiple myeloma; RVO=retinal vein occlusion; CSF=cerebrospinal fluid; PCR=polymerase chain reaction; SC=subcutaneous; *Results are event-driven, read-outs expected 2023/24

R&D focus area Alzheimer's disease

Clinical results for gantenerumab and blood-based biomarkers to be presented at CTAD

Pharmaceuticals

FDA BTD

gantenerumab

- Nearly two decades of scientific investigation with nearly 7000 patient years on treatment
- GRADUATE I/II: Patients with early AD (FDA BTD)
- SKYLINE: Patients at risk of, or at the earliest stages of AD

Brain shuttle gantenerumab

- Improve transport of gantenerumab across the blood brain barrier
- Promising Ph I PK data
- Platform technology: Ph I trial in MS with a CD20

Anti-tau mABs

- Different MoA, targeting tau protein tangles instead of Aß plaques
- Two assets (semorinemab & bepranemab) in Ph II trials

Diagnostics

FDA BDD

Blood-based biomarker

- Elecsys Amyloid Plasma Panel (FDA BDD)
- A minimally invasive test to help pre-select patients for confirmatory testing
- Runs on serum work area platforms

CSF-based biomarker

- Elecsys Aß and pTau CSF
- Confirmatory test equivalent to PET scan
- Runs on serum work area platforms

Multiple Real World Data (RWD) studies*

*Topics include natural history, predictors of progression in early AD, QoL across the AD continuum and more; Latest RWD study: Delphi study CONCORD-AD 2.0, connecting cohorts to diminish AD
AD=Alzheimer's disease; PK=pharmacokinetics; MS=multiple sclerosis; Aß=amyloid beta; BDD=breakthrough device designation; CSF=Cerebrospinal fluid; QoL=quality of life

2022 outlook confirmed

Group sales growth[1]	• Stable to low-single digit
Core EPS growth[1]	• Low- to mid-single digit
Dividend outlook	• Further increase dividend in Swiss francs

[1] At Constant Exchange Rates (CER)

Pharmaceuticals Division

Bill Anderson
CEO Roche Pharmaceuticals

YTD Sep 2022: Pharmaceuticals Division sales

New products compensate for loss-of-exclusivity and COVID-19 sales decline

	2022 CHFm	2021 CHFm	Change in % CHF	Change in % CER
Pharmaceuticals Division	**33,189**	**33,379**	**-1**	**0**
United States	17,199	16,707	3	-1
Europe	6,100	6,610	-8	-1
Japan	3,029	3,186	-5	7
International	6,861	6,876	0	0

CER=Constant Exchange Rates

YTD Sep 2022: Portfolio diversification accelerating



Absolute values and growth rates at Constant Exchange Rates (CER)

YTD Sep 2022: Oncology portfolio rejuvenation on-going



HER2 franchise

- Kadcyla (+11%) with growth ex-US due to adjuvant BC
- Perjeta (+5%) driven by International, especially APAC
- Phesgo (CHF 526m): 30% conversion in early launch countries

Tecentriq

- Growth (+10%) driven by adjuvant NSCLC, 1L HCC and 1L SCLC

Hematology franchise

- Venclexta*: Expanding patient share in 1L AML & R/R CLL
- Gazyva (+8%): Growth due to 1L FL and in 1L CLL
- Polivy (+79%): Strong 1L DLBCL uptake in early launch countries; PDUFA date for 1L DLBCL (POLARIX) set for Apr 2nd
- Lunsumio: Approved in EU with strong early launch in Germany and Austria; PDUFA set for Dec 29th

Alecensa

- Strong growth (+16%) and 1L ALK+ NSCLC leadership in major markets

YTD Sep 2022 Oncology sales: CHF 15.0bn; CER growth -1%; CER=Constant Exchange Rates; * Venclexta sales booked by AbbVie and therefore not included; Polivy in collaboration with Seagen; BC=breast cancer; HCC=hepatocellular carcinoma; NSCLC=non-small cell lung cancer; SCLC=small cell lung cancer; AML=acute myeloid leukemia; R/R CLL=relapsed/refractory chronic lymphocytic leukemia; FL=follicular lymphoma; DLBCL=diffuse large B cell lymphoma; PDUFA=Prescription Drug User Fee Act; ALK=anaplastic lymphoma kinase

HER2+ franchise: Continued growth

Multiple Ph III combination trials initiated

Phesgo's strong global launch continues



- Phesgo conversion rate at 30% in early launch countries
- Phesgo significantly cuts healthcare costs and resource use
- P+H in eBC (APHINITY): 8-year follow up data presented at ESMO Virtual Plenary showing a 28% reduction in the risk of recurrence or death for high risk, lymph-node positive patients
- Ph III (heredERA) Phesgo + giredestrant in 1L HER2+/HR+ mBC initiated

Kadcyla growth driven by adjuvant setting



- Continued growth enabled by global expansion in the adjuvant setting
- Kadcyla remains SoC in adjuvant patients with residual disease (KATHERINE) with > 60% of sales in the adjuvant setting
- Ph III (KATE-3) Kadcyla + Tecentriq in 2L+ HER2+/PD-L1+ mBC initiated
- Ph III (ASTEFANIA) Kadcyla + Tecentriq in HER2+/PD-L1+ eBC initiated

P=Perjeta; H=Herceptin; HR=Hormone receptor; HER2=Human epidermal growth factor receptor 2; BC=Breast cancer; eBC=Early breast cancer; mBC=Metastatic breast cancer; PCR=pathologic complete response; SoC=standard of care; ESMO=European Society for Medical Oncology; *Phesgo conversion rate is based on volumes (vials) and includes all launch countries after the 2nd quarter after the launch (25 countries); Phesgo in collaboration with Halozyme

Giredestrant: Early data support continued development in ER+ BC

Ph III (persevERA) interim results in 1L ER+ BC expected for 2024

Ph II (acelERA) results in 2/3L ER+/HER- BC



	giredestrant (n = 51)	PCET (n = 39)
HR (95% CI)	**0.60** (0.35, 1.03)	
p-value (log-rank)	0.0610	
mPFS, months	5.3	3.5

- PFS benefit was more pronounced in patients with *ESR1* mutations (HR of 0.81 in all-comers vs HR of 0.60 in patients with *ESR1* mutations)
- In 2L/3L setting patients have received multiple cycles of ET
- The activity observed in patients whose tumours still depend on estrogen receptor activity for viability is encouraging for earlier lines, where nearly all ER+ tumours are dependent on ER activity

Ph II (coopERA) results in neoadjuvant ER+/HER- BC



G+P, Giredestrant + Palbociclib; A+P, Anastrozole + Palbociclib

- First randomized study to show superior activity of an oral SERD (giredestrant) over an aromatase inhibitor (anastrozole) in ER+/HER2– eBC
- Final analysis confirmed greater suppression of Ki67 and rates of complete cell cycle arrest with giredestrant vs. anastrazole at time of surgery
- Ki67 is a biomarker of proliferation associated with improved long-term efficacy outcomes in early stage disease
- Safety data consistent with known safety profile

Fasching P et al., ASCO 2022; Martin M et al., ESMO 2022; Clinical cutoff: 18 Feb 2022; median follow-up 7.89 months; SERD=Selective estrogen receptor degrader; BC=Breast cancer; ER=estrogen receptor; ESR1=estrogen receptor 1; ET=estrogen therapy; PFS-INV=progression-free survival by investigator assessment; HR=hazard ratio; PCET=physician's choice of endocrine therapy; HER2=Human epidermal growth factor receptor 2

Tecentriq overview: Adjuvant key trials now to read out in 2023

First PD-(L)1 with pivotal SC results to be filed in 2022



Tecentriq Q3 update

- Positive Ph III (IMscin001) results for SC administration

Lung franchise (NSCLC, SCLC)

- EU: Strong launch in adj. NSCLC; 1L SCLC with continued growth
- US: Continued strong launch in adj. NSCLC

GI franchise (HCC)

- US/EU/Japan: Further growth in 1L HCC

Outlook 2022

- Further growth due to first-to-market indications

CER=Constant Exchange Rates; SC=subcutaneous; NSCLC=non-small cell lung cancer; SCLC=small cell lung cancer; HCC=hepatocellular cancer

Hemophilia A franchise: Hemlibra new global standard of care

36% US/EU-5 patient share reached



Hemophilia Q3 update

- >18,000 patients treated globally
- Hemlibra continues to penetrate across all approved patient segments
- 2nd generation FIXa x FX bi-specific (NXT007) to be taken into Roche clinical development

Outlook 2022

- US/EU: Further patient share gains in non-inhibitors
- EU: Label expansion to include mild/moderate patients (HAVEN 6) expected
- Ph III (HAVEN 7) in infants (0-1 year) submitted for presentation at ASH 2022

CER=Constant Exchange Rates

Immunology franchise

Actemra COVID-19 sales declining and Esbriet generic competition



Immunology Q3 updates

Actemra (-42%)

- COVID-19 demand completely washed out in Q3
- Submitted to EMA for approval in SSC-ILD
- Shift from IV to SC ongoing

Xolair (+8%)

- Market leader in asthma biologics and strong growth in CSU
- Autoinjector submitted to FDA for approval

Esbriet (-48%)

- US: Generic competition

CER=Constant Exchange Rates; RA=rheumatoid arthritis; IV=intravenous; SC=subcutaneous; CSU=chronic spontaneous urticaria; SSc-ILD=systemic sclerosis-interstitial lung disease

MS franchise: Ocrevus #1 treatment in US and now also in EU-5

MS development programs well on track



Q3 update

- >250.000 patients treated globally
- #1 treatment in US and EU-5, both in total share and new to brand share
- Higher persistence than other MS medicines
- Ph III program (FENhance I/II, FENtrepid) for fenebrutinib in RMS and PPMS on track
- Ph III (OCARINA II) Ocrevus SC with strong recruitment; results expected in 2023

Outlook 2022

- US/EU: Further market share gains expected

CER=Constant Exchange Rates; MS=multiple sclerosis; SC=subcutaneous; RMS=relapsing MS; PPMS=primary progressive MS

MS franchise: Subcutaneous dosing and higher dose Ocrevus

Q6M SC dosing readout expected in 2023

Ocrevus SC will retain Q6M dosing



Ocrevus higher dose vs 600 mg in RMS and PPMS



- Ph III (OCARINA II) evaluating subcutaneous Q6M dosing of Ocrevus for non-inferiority vs Ocrevus IV in RMS & PPMS with data expected in 2023
- Increases potential for Ocrevus use in centers with IV capacity constraints

- Two double-blind, randomized Ph III studies were designed to test higher dose Ocrevus (MUSETTE in RMS and GAVOTTE in PPMS)[1]
- Exposure/response analysis of Ph III data suggests a higher dose could lower the risk of disability progression without compromising safety

[1] Hauser S.L. et al, ACTRIMS-ECTRIMS 2020; †Expected, but may vary based on clinical results; MS=multiple sclerosis; IV=intra-venous; SC=Subcutaneous; RMS=relapsing multiple sclerosis; PPMS=primary progressive MS; Q6M=dosing every 6 months

SMA franchise: Evrysdi with strong global momentum

Well-positioned to become #1 worldwide



Q3 update

- >7,000 patients treated worldwide (commercial, clinical trials, compassionate use)
- Retention rate in first 12 months of ~90% globally
- US: Growth driven by switch and naive patient starts including patients <2 months old
- Ex-US: Continued strong growth and share gains in all major markets
- Positive Ph II (JEWELFISH) 2 year data presented at WMS; largest SMA study in previously treated patients

Outlook 2022

- Continued growth and market share gains across all market segments expected
- EU: Label extension (<2 months old) based on Ph II RAINBOWFISH expected

CER=Constant Exchange Rates; SMA=spinal muscular atrophy

Ophthalmology franchise: Excellent Vabysmo launch

More than 165k vials shipped in the US in the first 7 months



Q3 update

Vabysmo

- US: Strong uptake with switches primarily from aflibercept and first naïve patient starts
- US: Permanent J-code granted on October 1st
- EU: Approval granted in DME and nAMD
- Ph III (TENAYA/LUCERNE) 2 year data in nAMD presented at ASRS
- Real-world study (TRUCKEE*) update presented at AAO supporting efficacy and safety profile

Susvimo

- Voluntary recall due to manufacturing issue

Outlook 2022

- Ph III (BALATON / COMINO) results for Vabysmo in RVO expected
- Ph III (PAGODA/PAVILLION) results for Susvimo in DME/DR expected
- Ph III (MEERKAT/SANDCAT) IL-6 mAb in UME to be initiated

*Investigator initiated study; DME=diabetic macular edema; nAMD=neovascular age-related macular degeneration; RVO=retinal vein occlusion; DR=diabetic retinopathy; UME=uveitic macular edema; mAb=monoclonal antibody; Eylea (aflibercept) is a registered trademark/product of Regeneron

Vabysmo: Improved overall disease control in DME

Treat & extend study design well-aligned with clinical practice

Ph III trial design in DME (YOSEMITE/RHINE)



- First time treat & extend principals were consistently applied in a randomized Ph III setting aligned with clinical practice
- Share of patients on ≥Q12W dosing at 78% in year 2, with share of patients on Q16W dosing improving to 62% from 52% in year 1

Ph III (YOSEMITE/RHINE) 2 year results



- Improved disease control seen in anatomic outcomes vs aflibercept Q8W, maintained over two years
- Comparable BCVA gains vs aflibercept over two years, maintained with fewer injections in Vabysmo PTI arm

YOSEMITE (NCT03622580)/RHINE (NCT03622593). Test for superiority: * Nominal P < 0.05 versus aflibercept Q8W. P values are nominal and not adjusted for multiplicity; [a] CST was measured as the distance from the internal limiting membrane to Bruch's membrane. [b] BCVA was measured using the ETDRS visual acuity at a starting distance of 4 m. [c] Previously anti-VEGF-treated eyes (treated>= 3 months before day 1) were limited to 25% of the total enrolment. [d] Primary efficacy endpoint: adjusted mean BCVA change from baseline at year 1, averaged over weeks 48, 52 and 56. BCVA=best corrected visual acuity; CST=central subfield thickness; DME=diabetic macular edema; ETDRS=early diabetic retinopathy study; PTI=personalized treatment interval; Q8W=every 8 weeks; Eylea (aflibercept) is a registered trademark/product of Regeneron

Vabysmo: 2 year nAMD data presented at ASRS

Strong BCVA and CST results sustained over 2 years

Ph III trial design in nAMD (TENAYA/LUCERNE)



- Disease activity criteria at week 20 and 24 used to allocate patients to treatment intervals (Q8W or Q12W or Q16W) for the remainder of year 1
- During year 2, Vabysmo patients were treated via a personalized treatment interval regimen
- Share of patients on ≥Q12W dosing at 78% in year 2, with share of patients on Q16W dosing improving to 63% from 45% in year 1

Ph III (TENAYA/LUCERNE) 2 year results



- Rapidly improved anatomy in more patients on VABYSMO vs aflibercept during the matched Q4W loading period
- Comparable BCVA and CST gains vs aflibercept over two years, maintained with fewer injections for Vabysmo

Khanani A.M. et al., ASRS conference 2022; TENAYA (NCT03823287)/LUCERNE (NCT03823300): [a] BCVA was measured using the ETDRS visual acuity chart at a starting distance of 4 m; BCVA=best-corrected visual acuity; nAMD=neovascular age-related macular degeneration; CST=central subfield thickness; ETDRS=early diabetic retinopathy study; Q8W=every 8 weeks; ITT=intention to treat; Eylea (aflibercept) is a registered trademark/product of Regeneron

Vabysmo: Disease criteria chosen impact patient allocation

Vabysmo nAMD trials use disease criteria reflective of clinical practice[1]

Different ≥Q12W disease criteria as applied to TENAYA/LUCERNE patients

Stringent criteria**

*Treatment change if **ANY** criteria are met (based on criteria used in pivotal trials)*

- **≥ 5 letters BCVA loss** vs avg. BCVA over previous 2 scheduled visits, due to nAMD*
- OR
- **≥ 10 letters BCVA loss** vs highest BCVA recorded over previous 2 scheduled visits, due to nAMD*
- OR
- **> 50 µm CST increase** vs avg. CST over previous 2 scheduled visits
- OR
- **≥ 75 µm CST increase** vs lowest CST recorded at either of previous 2 scheduled visits
- OR
- **Presence of new macular hemorrhage***, due to nAMD activity

Less stringent criteria

*Treatment change if **ALL** criteria are met*

- **>5 letters BCVA loss** vs week 16 BCVA
- AND
- **> 25 µm CST increase** vs week 16 CST or new macular hemorrhage

Share of patients on ≥Q12W dosing

Assessment done at week 20



- Ph III TENAYA/LUCERNE trial with stringent patient-centric criteria resulted in 22% of patients being allocated to Q8W dosing
- Utilizing less stringent criteria only 4% of patients would have resulted in Q8W dosing (post hoc analysis)

[1]Heier et al. Lancet. 2022;399(10326):729-40; TENAYA (NCT03823287) & LUCERNE (NCT03823300); *per the investigator; **Additional patients with a missing Week 20 assessment were considered to have met disease activity criteria and were treated Q8W; Q8W=every 8 weeks; BCVA=best-corrected visual acuity; nAMD=neovascular age-related macular degeneration; CST=central subfield thickness

2022: Key late-stage news flow* and upcoming IR events

	Compound	Indication	Milestone	
Regulatory	**Vabysmo**	nAMD/DME	US/EU approval	✓
	Susvimo	nAMD	EU approval	Delayed
	Lunsumio (mosunetuzumab)	3L+ FL	US/EU approval	✓ EU
	Tecentriq	Adjuvant NSCLC	EU approval	✓
	Hemlibra	Mild to moderate hemophilia A	EU approval	
	Polivy + R-CHP	1L DLBCL	EU/US approval	✓ EU
Phase III / pivotal readouts	**glofitamab**	3L+ DLBCL	Ph Ib NP30179	✓
	Tecentriq + tiragolumab + chemo	1L ES-SCLC	Ph III SKYSCRAPER-02	✗
	Tecentriq + chemo	Adjuvant SCCHN	Ph III IMvoke010	2023
	Tecentriq + tiragolumab	1L PDL1+ NSCLC	Ph III SKYSCRAPER-01	Continues to OS IA
	Tecentriq	Adjuvant RCC	Ph III IMmotion010	✗
	giredestrant	2/3L HR+ mBC	Ph II acelERA	✗
	Tecentriq + Avastin	Adjuvant HCC	Ph III IMbrave050	2023
	Venclexta + dexamethasone	t(11;14) R/R MM	Ph III CANOVA	
	Tecentriq + chemo	Periadjuvant NSCLC	Ph III IMpower030	2023
	Tecentriq + tiragolumab + chemo	1L esophageal cancer	Ph III SKYSCRAPER-08 *(China only)*	2023
	Alecensa	Adjuvant ALK+ NSCLC	Ph III ALINA	2023
	gantenerumab	Alzheimer's disease	Ph III GRADUATE 1/2	
	Susvimo	DME / DR	Ph III PAGODA / PAVILION	
	Vabysmo	RVO	Ph III BALATON / COMINO	

Virtual event Angiogenesis ✓	***Virtual event MDA*** ✓	***Roche ESG Day Access to Healthcare*** ✓	***Virtual event ASCO*** ✓	***Roche Pharma Day London*** ✓	***Virtual event ASH***
Monday, 14 Feb *16:30 to 17:45 CEST*	***Wednesday, 16 Mar*** *16:30 to 17:30 CEST*	***Monday, 16 May*** *15:00 to 16:30 CEST*	***Monday, 6 Jun*** *16:00 to 17:30 CEST*	***Monday, 12 Sep*** *10:30 to 15:00 BST*	***Wednesday, 14 Dec*** *16:00 to 17:30 CET*

* Outcome studies are event-driven: timelines may change; OS=overall survival; IA=interim analysis

Diagnostics Division

Thomas Schinecker
CEO Roche Diagnostics

YTD Sep 2022: Diagnostics Division sales

Sales increase of +6% driven by base business and COVID-19 testing

	2022 CHFm	2021 CHFm	Change in % CHF	Change in % CER
Diagnostics Division	**13,848**	**13,305**	**4**	**6**
Core Lab[1]	5,833	5,677	3	5
Point of Care[1]	3,086	2,415	28	30
Molecular Lab[1]	2,735	3,030	-10	-8
Diabetes Care	1,219	1,294	-6	-3
Pathology Lab	975	889	10	10

CER=Constant Exchange Rates; underlying growth of Core Lab excluding Roche Information Solutions: +5%; [1] Sales in the Point of Care customer area include sales from the Liat business (POC molecular), and sales in the Core Lab customer area include sales from the Life Science Alliances, both previously shown as part of Molecular Lab customer area. The comparative information for 2021 has been updated accordingly. In Q1 21 POC molecular sales = 90mCHF, Q2 21=92mCHF, Q3 21=175mCHF, Q4 21=194mCHF. In Q1 21 LS Alliances = 21mCHF, Q2 21=23mCHF, Q3 21=23mCHF, Q4 21=20mCHF.

YTD Sep 2022: Diagnostics Division highlights

Growing from a high base in 2021



- Immunodiagnostics (+6%)
- Clinical Chemistry (+8%)
- Custom biotech (-8%)[3]

- POC Immunodiagnostics (+39%)
- POC Molecular[3] (+33%)

- qPCR&NAP (-28%)
- Virology (-7%)

- Blood glucose monitoring (-4%)
- Insulin delivery systems (+9%)

- Advanced staining (+8%)
- Companion diagnostics (+28%)

CER=Constant Exchange Rates; POC=point of care; [1] Underlying growth of Core Lab excluding Roche Information Solutions: +5%; [2] EMEA=Europe, Middle East and Africa; [3] Sales in Point of Care customer area include sales from the Liat business (POC molecular), and sales in the Core Lab customer area include sales from the Life Science Alliances, both previously shown as part of Molecular Lab customer area. The comparative information for 2021 has been updated accordingly. In Q1 21 POC molecular sales = 90mCHF, Q2 21=92mCHF, Q3 21=175mCHF, Q4 21=194mCHF. In Q1 21 LS Alliances = 21mCHF, Q2 21=23mCHF, Q3 21=23mCHF, Q4 21=20mCHF.

YTD Sep 2022: Diagnostics Division regional sales

Strong base business growth across all regions



Growth rates at CER (Constant exchange Rates); [1] Europe, Middle East and Africa

Diagnostics Division sales growth by quarter

Strong base business growth



Growth rates at CER (Constant exchange Rates); [1] Quarterly sales growth excluding COVID-19 sales

Our contribution against COVID-19

Roche has enabled access to >1.8 billion tests to fight the COVID-19 pandemic

20+ solutions

Broad portfolio of COVID-19 solutions

>1.8 billion COVID-19 tests

Conducted with our products since 2020

Responsible pricing to enable access

Costs should not be a barrier to access testing

~2'000 cobas® 6800/8800 instruments placed[1]

Increase over two-fold since the pandemic, enabling increased access to testing beyond COVID-19

Selected launches and acquisitions



[1] cobas® 6800/8800 instruments installed base per September 2022; [2] Elecsys® IGRA SARS-CoV-2 upcoming launch in end of July, 2022; [2] sensitivity of 99.00% (95% CI: 94.55 - 99.97%) and a relative specificity of 99.75% (95% CI: 98.62 - 99.99%); RUO: Research use only; POC: Point of care; EUA: Emergency Use Authorization; Ab: Antibody; Ag: Antigen

Roche Digital LightCycler®

Filling the gap between standard PCR and sequencing

Analyzer

Partition engine

Nanowell plates options:

1 

High sensitivity
~45µL sample, ~20k partitions

2 

Benchmark
~30µL sample, ~28k partitions

3 

High resolution
~15µL sample , ~100k partitions

- Digital PCR system with IVD label & superior performance
- Key differentiators:
  - Powerful analytical software & simpler workflow - no more emulsions
  - Flexibility to tailor assays from high sensitivity to high resolution needs
  - Industry-leading multiplexing capabilities
- High-medical value applications:
  - Cancer treatment monitoring
  - Transplant rejection monitoring
  - COVID-19 / Infectious diseases environmental surveillance

PCR: Polymerase chain reaction; IVD: In-vitro diagnostic

PRAME immunohistochemistry assay

Enabling optimal patient prognosis via early & accurate diagnosis and treatment of melanoma



- >300k new cases and ~60k death per year caused by Melanoma cancer[3]
- Key immunohistochemistry assay to:
  - Help differentiate between benign and malignant lesions in skin cancer[4,5]
  - Evaluate tumor margins in known melanoma specimens[4,5]
  - Evaluate sentinel lymph nodes in known melanoma cases[6,7]
- Localized melanoma is highly curable with a simple surgical excision
- Roche's broad dermatology portfolio includes >50 biomarkers

[1] American Cancer Society. https://www.cancer.org/cancer/melanoma-skin-cancer/detection-diagnosis-staging/survival-rates-for-melanoma-skin-cancer-by-stage.html; [2] Definitions of stages: 'Localized': There is no sign that the cancer has spread beyond the skin where it started. 'Regional': The cancer has spread beyond the skin where it started to nearby structures or lymph nodes. 'Distant': The cancer has spread to distant parts of the body, such as the lungs, liver, or skin on other parts of the body. [3] Cazzato G. et al. Genes. 2022;13: 545; [4] Lezcano, C. et al. Am J Surg Pathol 2018;42(11):1456-1465; [5] Lezcano, C. et al. Surg Pathol Clin 2021 Jun;14(2):165-175; [6] Lezcano, C. et al. Am J Surg Pathol 2020;44(4):503-508; [7] NCCN Guidelines Version 3.2022. PRAME: Preferentially expressed Antigen in Melanoma

Elecsys® Amyloid Plasma Panel clinical results

Addressing the unmet need of early detection of Alzheimer's disease pathology

1 Triage
Patients undergoing initial evaluation for non-specific cognitive decline[1]

Elecsys® Amyloid Plasma Panel[2]
pTau181 + APOE4

FDA BDD

sensitivity > 85%
specificity > 65%

2 Confirmation
Patients referred for amyloid confirmatory testing[3]

Elecsys® CSF AD assays[4]
pTau/Abeta 42

sensitivity > 90%
specificity > 90%

3 Therapy
Patients identified for future therapies

Anti-amyloid antibodies



[1] Assumed prevalence of AD 30% in symptomatic patients; [2] Mean of clinical performance data from retrospective cohorts measured with Elecsys Amyloid Plasma Panel; [3] Alternative to PET scan; [4] FDA approval expected in Q4 2022

= 10 patients

Key launches 2022

	Area	Product	Description	Market	Status
Instruments	Pathology Lab	BenchMark ULTRA PLUS	Automated immunohistochemistry/in situ hybridization (ISH) advanced staining platform with enhanced software capabilities, workflow and testing efficiency	US & CE	✓
		DP600	High capacity pathology slide scanner for high volume digitization applications	WW	✓
	Core Lab	cobas® pure integrated solutions	Serum work area analyzer for low-to-medium sized labs	US	✓
	Molecular Lab	cobas® 5800	Real-time PCR molecular testing for low volume labs	US	
		Digital LightCycler	Novel digital PCR platform for lab developed tests (LDTs) and in-vitro diagnostics labs	WW	✓
	POC	cobas® pulse	Handheld device combining professional Glucose Meter and a digital platform to host Roche owned and 3rd party digital clinical decision support applications	US	
Tests	Pathology Lab	HER2 Low Breast*	Assay for diagnosis of HER2 low expression breast cancer	US	✓
		PRAME**	First immunohistochemistry assay for differential diagnosis of benign from malignant melanocytic lesions in skin cancer	US & CE	✓
		HPV Self Sampling	Self sample collection device for patients at home to collect sample for cervical cancer testing	CE	✓
	Core Lab	cobas® HCV Duo	Antigen/antibody combined assay for faster diagnosis of hepatitis C	CE	✓
		Elecsys pTau/AB42 ratio Gen2 (CSF)	Detect amyloid disease and enable a broader availability of testing for patients suspected of Alzheimer's Disease	US	
	Molecular Lab	cobas® SARS-CoV-2 DUO	Automated RT-PCR assay for use on the cobas® 6800/8800 systems	US[2] & OUS[1]	✓
		cobas® 5800 Menu Expansion	Assays to test for SARS-CoV-2, chlamydia trachomatis (CT)/neisseria gonorrhoeae (NG) and cytomegalovirus (CMV)	US & CE	
Digital Solutions	Lab Insights	Navify Kidney Companion	Digital solution providing insights for chronic kidney disease patient management	CE	
		Cervical Cancer Screening	Digital solution improving the management of screening programs for cervical cancer	CE	
		cobas® infinity edge suite	Portfolio of digital products to support decentralization of testing and data, to launch commercially with an open ecosystem	CE	✓
		Navify Core Integrator	Data integration platform for laboratory customers across disciplines	CE	
	Diabetes Care	Payer Dashboard	Population-level insights via dashboard for HCPs, Admins and Payers	OUS[3]	✓
		mySugr Pump V2.0	Extended functionalities (e.g. temporary basal rate import from a connected insulin pump), expanded smartphone compatibility	OUS[3]	

CE: European Conformity, US: FDA approval, WW: Worldwide including CE, US and China, OUS: Outside the US; PCR: Polymerase Chain Reaction; RT: Real Time; [1]Research Use Only; [2] EUA: Emergency Use Authorization; [3]Only selected countries; *HER2 Low Breast received FDA approval on 4 Oct 2022; **PRAME launched on 11 Oct 2022

Finance

Alan Hippe
Chief Financial Officer

YTD Sep 2022: Highlights

Sales

- Group sales growth of +2%
- Solid Pharma and Diagnostics underlying growth

Currency impact on sales

- Negative currency impact especially in Q3, particularly weaker EUR and JPY, only partially offset by stronger USD

Growth rates at CER (Constant exchange Rates)

YTD Sep 2022: Portfolio rejuvenation ongoing



Diversification of Roche business



YTD Sep 2022 values in reported CHFm, variances in CERm; [1] AHR: Avastin, Herceptin, Rituxan/MabThera sales erosion

YTD Sep 2022: Regional sales development



Absolute values in CHFm at Constant Exchange Rates (avg full year 2021); [1] avg. full year 2021 to avg YTD September 2022 fx impact

YTD exchange rate swings

Negative impact driven by the EUR, JPY and other Europe, partially offset by USD



CER = Constant Exchange Rates (avg full year 2021)

Expected currency impact 2022



Assuming the 30 September 2022 exchange rates remain stable until end of 2022, 2022 impact[1] is expected to be (%p):

	Q1	HY	Sep YTD	FY
Sales	-1	0	-1	-1
Core operating profit		0		-2
Core EPS		0		-2

[1] On group growth rates

2022 outlook

Group sales growth[1]	• Stable to low-single digit
Core EPS growth[1]	• Low- to mid-single digit
Dividend outlook	• Further increase dividend in Swiss francs

[1] At Constant Exchange Rates (CER)

Doing now what patients need next

Roche Group development pipeline

Marketed products development programmes

Roche Pharma global development programmes

Roche Pharma research and early development (pRED)

Genentech research and early development (gRED)

Spark

Pharma sales appendix

Diagnostics sales appendix

Foreign exchange rates information

Changes to the development pipeline

Q3 2022 update

New to phase I

2 NMEs:
RG6536 vixarelimab – immunology
RG6538 P-BCMA-ALLO1 – multiple myeloma

New to phase II

1 NME:
RG7314 balovaptan – post-traumatic stress disorder

New to phase III

4 AIs:
RG6168 Enspryng – MOG-AD
RG6168 Enspryng – autoimmune encephalitis
RG6058 tiragolumab – 1L non-squamous NSCLC (SKYSCRAPER-06)
RG3625 TNKase – stroke (FPI 2019)

New to registration

1 NME (First filed in China*):
RG6017 crovalimab - PNH

Removed from phase I

Removed from phase II

2 NMEs:
RG7907 CpAM (2) – HBV
RG6147 galegenimab (HtrA1) – geographic atrophy

1 AI (removed by Chugai):
CHU Oncolytic Type 5 adenovirus – esophageal cancer

Removed from phase III

1 AI:
RG7446 Tecentriq – RCC adj

Approvals

1 NME (EU):
RG7716 Vabysmo - DME

1 AI (EU):
RG7716 Vabysmo – wAMD

1 AI (US):
RG6512 Xofluza - influenza pediatric

Status as of October 18, 2022

*US/EU filing expected 2023

Roche Group development pipeline

Phase I (51 NMEs + 11 AIs)

RG6007	HLA-A2-WT1 x CD3	AML
RG6026	glofitamab monotherapy + combos	heme tumors
RG6058	tiragolumab combos	heme & solid tumors
RG6076	CD19-4-1BBL combos	heme tumors
RG6129	HLA-A2-MAGE-A4 x CD3	solid tumors
RG6160	cevostamab (FcRH5 x CD3)	r/r multiple myeloma
RG6171	giredestrant (SERD)	solid tumors
RG6114	inavolisib (mPI3K alpha inh)	solid tumors
RG6156	EGFRvIII x CD3	glioblastoma
RG6180	autogene cevumeran ± T	solid tumors
RG6185	belvarafenib (pan-RAF inh) + Cotellic ± T	solid tumors
RG6189	FAP-CD40 ± T	solid tumors
RG6194	runimotamab (HER2 x CD3)	BC
RG6234	GPRC5D x CD3	multiple myeloma
RG6264	Phesgo OBI	HER2+ BC
RG6279	PD1-IL2v ± T	solid tumors
RG6286	-	colorectal cancer
RG6290	MAGE-A4 ImmTAC ± T	solid tumors
RG6292	CD25 MAb combos	heme & solid tumors
RG6323	IL15/IL15Ra-Fc ± T	solid tumors
RG6330	KRAS G12C	solid tumors
RG6333	CD19 x CD28 + glofitamab	r/r NHL
RG6344	BRAF inhibitor (3)	solid tumors
RG6392	-	oncology
RG6433	SHP2i combos	solid tumors
RG6440	TGFβ (SOF10)	solid tumors
RG6512	FIXa x FX	hemophilia
RG6526[1]	camonsertib	solid tumors
RG6538[2]	P-BCMA-ALLO1	multiple myeloma
RG7446	Morpheus platform	solid tumors
RG7601	Venclexta ± azacitidine	r/r MDS
RG7802	cibisatamab ± T	solid tumors
RG7827	FAP-4-1BBL monotherapy + combos	solid tumors
RG7828	Lunsumio (mosunetuzumab) monotheraphy + combos	heme tumors
CHU	glypican-3 x CD3	solid tumors
CHU	codrituzumab	HCC
CHU	CD137 switch antibody	solid tumors
CHU	LUNA18	solid tumors
CHU	SPYK04	solid tumors
SQZ	PBMC vaccine	solid tumors
RG6287	-	IBD
RG6341	-	asthma
RG6418	selnoflast (NLRP3 inh)	inflammation
RG6315	-	immunologic disorders
RG6536[3]	vixarelimab	immunology
RG7828	Lunsumio (mosunetuzumab)	SLE
RG7880	efmarodocokin alfa	aGVHD
RG6006	Abx MCP	bacterial infections
RG6319	LepB inhibitor	complicated urinary tract infection
RG6035	BS-CD20 MAb	multiple sclerosis
RG6091	rugonersen (UBE3A LNA)	Angelman syndrome
RG6163	-	psychiatric disorders
RG6182	-	neurodegenerative diseases
RG6237	latent myostatin	neuromuscular disorders
RG6289	-	Alzheimer´s
RG7637	-	psychiatric disorders
RG6120	VEGF-Ang2 DutaFab	nAMD
RG6312	-	geographic atrophy
RG6351	-	retinal disease
RG6501[4]	OpRegen	geographic atrophy
RG7921	-	nAMD
CHU	AMY109	endometriosis

Status as of October 18, 2022

New Molecular Entity (NME)
Additional Indication (AI)
Oncology / Hematology
Immunology
Infectious Diseases
Metabolism
Neuroscience
Ophthalmology
Other

Phase II (21 NMEs + 8 AIs)

RG6026	glofitamab + chemo	1L ctDNA high risk DLBCL
RG6058	tiragolumab + T	NSCLC
	tiragolumab + T + chemo	NSCLC neoadj-adj
	tiragolumab + T	cervical cancer
	tiragolumab + T	1L PD-L1+ mSCCHN
RG6107	crovalimab	sickle cell disease
RG6139	PD1 x LAG3	solid tumors
RG6180	autogene cevumeran + pembrolizumab	1L melanoma
RG6354	zinpentraxin alfa (PRM-151)	myelofibrosis
RG6357	SPK-8011	hemophilia A
RG6358	SPK-8016	hemophilia A with inhibitors to factor VIII
RG6149	astegolimab (Anti-ST2)	COPD
RG6299[5]	ASO factor B	IgA nephropathy
RG7854/ RG6346/ RG6084*	TLR7 ago(3)/siRNA/PDL1 LNA	HBV
RG6359	SPK-3006	Pompe disease
RG6100	semorinemab	Alzheimer's
RG6102	BS-gantenerumab	Alzheimer's
RG6237	latent myostatin + Evrysdi	SMA
RG6416	bepranemab	Alzheimer's
RG7314	balovaptan	post-traumatic stress disorder
RG7412	crenezumab	familial Alzheimer's healthy pts
RG7816	alogabat (GABA Aa5 PAM)	ASD
RG7906	ralmitaront	schizophrenia
RG7935	prasinezumab	Parkinson's
RG6179	anti-IL-6	DME
RG7774	CB2 receptor agonist	DR
RG6299[5]	ASO factor B	geographic atrophy

RG-No - Roche/Genentech
CHU - Chugai managed
SQZ - SQZ Biotechnology managed
[1]Repare Therapeutics managed
[2]Poseida Therapeutics managed
[3]Kiniksa Pharmaceuticals managed
[4]Lineage Cell Therapeutics managed
[5]IONIS managed

*combination platform
T=Tecentriq
BS=Brain Shuttle
OBI=On-Body Delivery System

Roche Group development pipeline

Phase III (10 NMEs + 46 AIs)

RG3502	Kadcyla + T	2L+ HER-2+ PD-L1+ mBC
	Kadcyla + T	HER-2+ eBC high-risk
RG6026	glofitamab + chemo	2L+ DLBCL
RG6058	tiragolumab + T	1L PD-L1+ NSCLC
	tiragolumab + T	1L esophageal cancer
	tiragolumab + T	locally advanced esophageal cancer
	tiragolumab + T	stage III unresectable 1L NSCLC
	tiragolumab + T	1L non-squamous NSCLC
RG6107	crovalimab*	PNH
	crovalimab	aHUS
RG6114	inavolisib (mPI3K alpha inh)	1L HR+ mBC
RG6171	giredestrant (SERD)	1L ER+/HER2- mBC
	giredestrant (SERD)	ER+ BC adj
	giredestrant (SERD) + Phesgo	1L ER+/HER2+ BC
RG7440	ipatasertib + abiraterone	1L CRPC
RG7446	Tecentriq + platinum chemo	NSCLC periadj
	Tecentriq	NMIBC, high risk
	Tecentriq + cabozantinib	RCC adv
	Tecentriq + cabozantinib	2L NSCLC
	T ± chemo	SCCHN adj
	T + capecitabine or carbo/gem	1L TNBC
	T + paclitaxel	TNBC adj
	T + Avastin	HCC adj
	T ± chemo	1L mUC
	Tecentriq SC	2L NSCLC
	Tecentriq	ctDNA+ high-risk MIBC
	T+ lurbinectedin	1L maintenance SCLC
RG7601	Venclexta	r/r MM t(11:14)
	Venclexta + azacitidine	1L MDS
RG7828	Lunsumio (mosunetuzumab) + lenalidomide	2L+ FL
	Lunsumio (mosunetuzumab) + Polivy	2L+ DLBCL
RG7853	Alecensa	ALK+ NSCLC adj
RG3648	Xolair	food allergy
RG6354	zinpentraxin alfa (PRM-151)	IPF
RG7159	Gazyva	lupus nephritis
	Gazyva	membranous nephropathy
	Gazyva	systemic lupus erythematosus
RG6152	Xofluza	influenza, pediatric (0-1 year)
	Xofluza	influenza direct transmission
RG1450	gantenerumab	prodromal to mild Alzheimer's
	gantenerumab	preclinical Alzheimer's
RG1594	Ocrevus higher dose	RMS & PPMS
	Ocrevus SC	RMS & PPMS
RG3625	TNKase	stroke
RG6042	tominersen	Huntington's
RG6168	Enspryng	myasthenia gravis
RG6168	Enspryng	MOG-AD
RG6168	Enspryng	autoimmune encephalitis
RG6356	delandistrogene moxeparvovec (SRP-9001)	DMD
RG7845	fenebrutinib	RMS
RG7845	fenebrutinib	PPMS
RG6321	Susvimo (PDS)	DME
	Susvimo (PDS)	DR
	Susvimo (PDS)	wAMD, 36-week
RG7716	Vabysmo (faricimab)	BRVO
	Vabysmo (faricimab)	CRVO

New Molecular Entity (NME)
Additional Indication (AI)
Oncology / Hematology
Immunology
Infectious Diseases
Metabolism
Neuroscience
Ophthalmology
Other

Registration US & EU (3 NMEs + 7AIs)

RG6013	Hemlibra[1]	mild to moderate hemophilia A
RG6026	glofitamab[2]	3L+ DLBCL
RG6396	Gavreto[1]	RET+ MTC, TC
RG7596	Polivy[3]	1L DLBCL
RG7828	Lunsumio (mosunetuzumab)[3]	3 L+ FL
RG6321	Susvimo (PDS)[1]	wAMD
RG6152	Xofluza[1]	influenza, pediatric
RG56413+ RG6412	Ronapreve[2]	SARS-CoV-2 hospitalised
RG1569	Actemra[3]	COVID-19 pneumonia
RG7916	Evrysdi[1]	SMA pediatric <2months

[1]Approved in US, filed in EU
[2]Filed in EU
[3]Approved in EU, filed in US

T=Tecentriq
PDS=Port Delivery System with ranibizumab
*First filed in China

Status as of October 18, 2022

NME submissions and their additional indications

Projects in phase II and III

New Molecular Entity (NME)
Additional Indication (AI)
Oncology / Hematology
Immunology
Infectious Diseases
Metabolism
Neuroscience
Ophthalmology
Other

✓ Indicates submission to health authorities has occurred
Unless stated otherwise submissions are planned to occur in US and EU
PDS=Port Delivery System with ranibizumab
Mosun=mosunetuzumab
*First filed in China
[1]IONIS managed

2022

RG6026	**glofitamab** 3L+ DLBCL ✓
RG6107	**crovalimab*** PNH (CN) ✓
RG1450	**gantenerumab** prodromal to mild Alzheimer‘s

2023

RG6107	**crovalimab*** PNH (EU, US)
RG6058	**tiragolumab + T** 1L PD-L1+ NSCLC
RG6058	**tiragolumab + T** 1L esophageal cancer (CN)
RG6321	**Susvimo (PDS)** DME
RG6321	**Susvimo (PDS)** DR (US)
RG7716	**Vabysmo (faricimab)** BRVO/CRVO

2024

RG6026	**glofitamab + chemo** 2L DLBCL
RG6058	**tiragolumab + T** Stage III unresectable 1L NSCLC
RG6107	**crovalimab** aHUS
RG6114	**inavolisib (mPI3K alpha inh)** 1L HR+ BC
RG6354	**zinpentraxin alfa (PRM-151)** IPF
RG6356	**delandistrogene moxeparvovec (SRP-9001)** DMD (EU)

2025 and beyond

RG6026	**glofitamab + chemo** 1L ctDNA+ high risk DLBCL
RG6058	**tiragolumab + T** 1L PD-L1+ cervical cancer
RG6058	**tiragolumab + T** locally adv esophageal cancer
RG6058	**tiragolumab + T** 1L non-sq NSCLC
RG6058	**tiragolumab + T** 1L PD-L1+ mSCCHN
RG6058	**tiragolumab+T+/- chemo** NSCLC neoadj/adj
RG6107	**crovalimab** sickle cell disease
RG6139	**PD1xLAG3** solid tumors
RG6171	**giredestrant (SERD)** 1L ER+/HER2- mBC
RG6171	**giredestrant (SERD)** ER+ BC adj
RG6171	**giredestrant (SERD) + Phesgo** 1L ER+/HER2+ BC
RG6180	**autogene cevumeran** 1L melanoma
RG6354	**zinpentraxin alfa (PRM-151)** myelofibrosis
RG7828	**Lunsumio (mosun) + lenalidomide** 2L FL
RG7828	**Lunsumio (mosun) + Polivy** 2L+ DLBCL (US)
RG6149	**astegolimab (anti-ST2)** COPD
RG6299[1]	**ASO factor B** IgA nephropathy
RG7854/ RG6346/ RG6084	**TLR7 ago (3)/ siRNA/ PDL1 LNA** HBV
RG1450	**gantenerumab** preclinical Alzheimer‘s
RG6100	**semorinemab** Alzheimer’s
RG6102	**brain shuttle gantenerumab** Alzheimer’s
RG6237	**latent myostatin + Evrysdi** SMA
RG6416	**bepranemab** Alzheimer's
RG7314	**balovaptan** post-traumatic stress disorder
RG7816	**alogabat (GABA Aa5 PAM)** ASD
RG7845	**fenebrutinib** RMS
RG7845	**fenebrutinib** PPMS
RG7906	**ralmitaront** schizophrenia
RG7935	**prasinezumab** Parkinson’s
RG6321	**Susvimo (PDS)** wAMD, 36-week refill
RG6179	**anti-IL-6** DME
RG6299[1]	**ASO factor B** geographic atrophy
RG7774	**CB2 receptor agonist** DR

Status as of October 18, 2022

AI submissions for existing products

Projects in phase II and III

New Molecular Entity (NME)
Additional Indication (AI)
Oncology / Hematology
Immunology
Infectious Diseases
Metabolism
Neuroscience
Ophthalmology
Other

2022		2023		2024		2025 and beyond	
RG6413+ RG6412	**Ronapreve**** SARS-CoV-2 hospitalized (EU) ✓	RG6264	**Phesgo OBI** HER2+ BC	RG1594	**Ocrevus SC** RMS & PPMS	RG7446	**Tecentriq + paclitaxel** TNBC adj	RG3502	**Kadcyla + Tecentriq** 2L+ HER-2+ PD-L1+ mBC
RG1569	**Actemra** COVID-19 pneumonia[1] ✓	RG6396	**Gavreto** Tumor agnostic (US)	RG3625	**TNKase** stroke	RG7446	**Tecentriq** ctDNA+ high-risk MIBC	RG3502	**Kadcyla + Tecentriq** HER-2+ eBC high-risk
RG7446	**Tecentriq ± chemo** 1L mUC	RG7446	**Tecentriq + cabozantinib** 2L NSCLC	RG3648	**Xolair** food allergy	RG7601	**Venclexta + azacitidine** 1L MDS	RG7446	**Tecentriq** High risk NMIBC
RG7446	**Tecentriq SC** 2L NSCLC	RG7446	**Tecentriq + cabozantinib** RCC adv	RG6152	**Xofluza** direct transmission	RG7159	**Gazyva** lupus nephritis	RG7446	**Tecentriq+ lurbinectedin** 1l maintenance SCLC
RG7596	**Polivy** 1L DLBCL (US) ✓	RG7446	**Tecentriq + Avastin** HCC adj	RG6152	**Xofluza** influenza, pediatric (0-1 year)	RG6168	**Enspryng** myasthenia gravis	RG7159	**Gazyva** membranous nephropathy
		RG7446	**Tecentriq**[2] NSCLC periadj					RG7159	**Gazyva** systemic lupus erythematosus
		RG7446	**Tecentriq** SCCHN adj					RG1594	**Ocrevus higher dose** RMS & PPMS
		RG7601	**Venclexta** r/r MM t(11:14)					RG6168	**Enspryng** MOG-AD
		RG7446	**Tecentriq + capecitabine or carbo/gem** TNBC					RG6168	**Enspryng** autoimmune encephalitis
		RG7853	**Alecensa** ALK+ NSCLC adj						

Status as of October 18, 2022

✓ Indicates submission to health authorities has occurred
Unless stated otherwise submissions are planned to occur in US and EU
[1]Approved in EU, filed in US
[2]filing timeline based on data from interim analysis

PDS=Port Delivery System with ranibizumab
OBI=On-Body Delivery System
**Ronapreve (casirivimab+imdevimab also known as REGEN-COV in the US) developed in collaboration with Regeneron Pharmaceuticals

Major pending approvals 2022

US		EU		China		Japan-Chugai	
RG7828	**Lunsumio (mosunetuzumab)** 3L+ FL Filed Dec 2021	RG6321	**Susvimo (PDS)** wAMD Filed April 2021	RG7596	**Polivy** 1L DLBCL Filed Nov 2021	RG7159	**Gazyva** 1L CLL Filed March 2022
RG1569	**Actemra** COVID-19 pneumonia Filed Jan 2022	RG6013	**Hemlibra** mild to moderate hemophilia A Filed Oct 2021	RG7596	**Polivy** r/r DLBCL Filed Dec 2021	RG6264	**Phesgo** HER-2+ BC/CC Filed Sept 2022
RG7421	**Cotellic** histiocytosis Filed April 2022	RG6396	**Gavreto** RET+ MTC, TC Filed Nov 2021	RG6107	**crovalimab** PNH Filed Aug 2022		
RG7446	**Tecentriq** ASPS Filed June 2022	RG6152	**Xofluza** influenza pediatric Filed Nov 2021				
RG7596	**Polivy** 1L DLBCL (US) Filed Aug 2022	RG7916	**Evrysdi** SMA presymptomatic pediatric <2mo Filed Nov 2021				
		RG6413+ RG6412	**Ronapreve*** SARS-CoV-2 hospitalized Filed Jan 2022				
		RG6026	**glofitamab** 3L+ DLBCL Filed April 2022				
		RG1569	**Actemra** SS-ILD Filed Aug 2022				

New Molecular Entity (NME)
Additional Indication (AI)
Oncology / Hematology
Immunology
Infectious Diseases
Metabolism
Neuroscience
Ophthalmology
Other

PDS=Port Delivery System with ranibizumab
*Ronapreve (casirivimab+imdevimab also known as REGEN-COV in the US) developed in collaboration with Regeneron Pharmaceuticals

Status as of October 18, 2022

Major granted approvals 2022

US	
RG7716	**Vabysmo (faricimab)** DME Jan 2022
RG7716	**Vabysmo (faricimab)** wAMD Jan 2022
RG1569	**Actemra** GCA IV Feb 2022
RG7916	**Evrysdi** SMA presymptomatic pediatric <2mo May 2022
RG6152	**Xofluza** influenza pediatric Aug 2022

EU	
RG7596	**Polivy** 1L DLBCL May 2022
RG7446	**Tecentriq** NSCLC adj June 2022
RG7828	**Lunsumio (mosunetuzumab)** 3L+ FL June 2022
RG7716	**Vabysmo (faricimab)** DME Sept 2022
RG7716	**Vabysmo (faricimab)** wAMD Sept 2022

China	
RG7446	**Tecentriq** NSCLC adj March 2022
RG1569	**Actemra** RA SC April 2022
RG6268	**Rozlytrek** NTRK+ solid tumors July 2022
RG6268	**Rozlytrek** ROS1+ NSCLC Aug 2022

Japan-Chugai	
RG1569	**Actemra** COVID-19 pneumonia Jan 2022
RG7716	**Vabysmo (faricimab)** DME March 2022
RG7716	**Vabysmo (faricimab)** wAMD March 2022
RG1273	**Perjeta + Herceptin** HER-2+ CRC March 2022
RG7446	**Tecentriq** NSCLC adj May 2022
RG6013	**Hemlibra** acquired Hemophilia A June 2022
RG105	**Rituxan** NMOSD June 2022
RG7596	**Polivy** 1L DLBCL Aug 2022

New Molecular Entity (NME)
Additional Indication (AI)
Oncology / Hematology
Immunology
Infectious Diseases
Metabolism
Neuroscience
Ophthalmology
Other

Status as of October 18, 2022

Doing now what patients need next